Vertex's experimental pain drug fails main goal in mid-stage study
ReutersAug 4, 2025 8:06 PM
Aug 4 (Reuters) - Vertex Pharmaceuticals VRTX.O said on Monday its next generation oral drug failed to meet the main goal of a keenly-watched mid-stage trial.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
AppLovin Q2 FY2025 Earnings Preview: Can AI-Powered AdTech Fuel Another Surge?
TradingKey - AppLovin (NASDAQ: APP) is set to report its Q2 FY2025 earnings on Wednesday, August 6, 2025, after the U.S. market closes. The earnings call will begin at 5:00 p.m. Eastern Time, hosted by CEO Adam Foroughi and CFO Matthew Stumpf.TradingKey
17 hours ago
FedEx Corp (FDX): Waiting for the Spin-off
TradingKey - Parcel delivery, the main business of FedEx, is a difficult industry with low margins and low bargaining power against larger e-commerce clients, thus the current low multiple.TradingKey
17 hours ago
U.S. Stock Sector Strategy: The Outlook for Tech Stocks from a Macro Perspective
TradingKey - Against the backdrop of easing trade war tensions, sustained economic resilience, and the Federal Reserve's anticipated interest rate cuts, the U.S. stock market is expected to maintain its upward trajectory. At the sector level, we are optimistic about U.S. technology stocks...TradingKey
22 hours ago
AMD Q2 FY2025 Earnings Preview: AI and Data Center Growth Prospects in Focus
TradingKey - Advanced Micro Devices, Inc. (NASDAQ: AMD) is scheduled to report its Q2 FY2025 earnings on Tuesday, August 5, 2025, after the U.S. market closes. The earnings call will begin at 5:00 p.m. Eastern Time.TradingKey
Fri, Aug 1
